Barinthus Biotherapeutics (BRNS) Shares Outstanding (Diluted Average) (2022 - 2026)
Barinthus Biotherapeutics filings provide 5 years of Shares Outstanding (Diluted Average) readings, the most recent being $40.8 million for Q1 2026.
- On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.45% to $40.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $40.8 million, a 1.45% increase, with the full-year FY2025 number at $40.5 million, up 3.0% from a year prior.
- Shares Outstanding (Diluted Average) hit $40.8 million in Q1 2026 for Barinthus Biotherapeutics, up from $40.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $40.8 million in Q1 2026 to a low of $38.0 million in Q1 2023.
- Median Shares Outstanding (Diluted Average) over the past 5 years was $38.9 million (2024), compared with a mean of $39.2 million.
- Biggest five-year swings in Shares Outstanding (Diluted Average): increased 0.1% in 2023 and later grew 3.85% in 2025.
- Barinthus Biotherapeutics' Shares Outstanding (Diluted Average) stood at $38.2 million in 2022, then increased by 0.57% to $38.4 million in 2023, then grew by 2.51% to $39.3 million in 2024, then increased by 3.0% to $40.5 million in 2025, then grew by 0.79% to $40.8 million in 2026.
- The last three reported values for Shares Outstanding (Diluted Average) were $40.8 million (Q1 2026), $40.5 million (Q4 2025), and $40.7 million (Q3 2025) per Business Quant data.